Patient-Centric Mission.
Asset-Centric Approach.
We’re pursuing our Orexin Receptor 2 Agonist Program to bring potentially transformative treatment options to patients with sleep-wake disorders.
Patient-Centric Mission.
Asset-Centric Approach.
We’re pursuing SerpinPC as a potential novel subcutaneous treatment for hemophilia B patients with potential expansion into other bleeding disorders.
Patient-Centric Mission.
Asset-Centric Approach.
We’re pursuing our LockBody® Technology Platform with the aim to redefine immuno-oncology treatment for patients with cancer.
We are leaders, innovators, and scientists aiming to pursue medicines that are transformational for patients.
Latest News
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers